Atrasentan in Patients with Advanced Renal Cell Carcinoma: A Phase II Trial of the ECOG-ACRIN Cancer Research Group (E6800)

OBJECTIVES: Atrasentan, an oral endothelin-A receptor antagonist, demonstrated Phase I activity in patients with renal cell cancer (RCC). A phase II study was undertaken in patients with measurable or bone only metastatic RCC in the pre-VEGF/TKI era. METHODS AND MATERIALS: Patients were stratified o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Carducci, Michael A., Manola, Judith, Nair, Suresh G., Liu, Glenn, Rousey, Steven, Dutcher, Janice P., Wilding, George
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4637227/
https://ncbi.nlm.nih.gov/pubmed/26272427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2015.07.002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados